Zdrowie i gospodarka · 29/05/2025
FDA Classifies Zika Virus Serological Reagents into Class II with Special Controls
The FDA is classifying Zika virus serological reagents into Class II with special controls to ensure safety and effectiveness, aiming to reduce regulatory burdens and enhance patient access to innovative devices.
Source: Federal Register — Food and Drug AdministrationOpen original release →